Theranostics 2017; 7(9):2524-2536. doi:10.7150/thno.19856 This issue Cite

Research Paper

Rapid In Situ MRI Traceable Gel-forming Dual-drug Delivery for Synergistic Therapy of Brain Tumor

Feng-Wei Lin1*, Pin-Yuan Chen2*, Kuo-Chen Wei3, Chiung-Yin Huang3, Chih-Kuang Wang4, Hung-Wei Yang1✉

1. Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, Taiwan;
2. Department of Neurosurgery, Chang Gung Memorial Hospital, Keelung 20401, Taiwan
School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan
3. Department of Neurosurgery, Linkou Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan. School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan;
4. Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
* These authors contributed equally.

Citation:
Lin FW, Chen PY, Wei KC, Huang CY, Wang CK, Yang HW. Rapid In Situ MRI Traceable Gel-forming Dual-drug Delivery for Synergistic Therapy of Brain Tumor. Theranostics 2017; 7(9):2524-2536. doi:10.7150/thno.19856. https://www.thno.org/v07p2524.htm
Other styles

File import instruction

Abstract

Graphic abstract

Preventing tumor recurrence after surgical resection of a brain tumor is a significant clinical challenge because current methods deliver chemotherapeutic agents in a rapid manner and are not effective against the residual tumor cells. To overcome this drawback, we report a simple method to prepare magnetic resonance imaging (MRI) traceable ultra-thermosensitive hydrogels with rapid gelation ability from aqueous solution within 4 s at 28 °C for hydrophilic (epirubicin, EPI) and hydrophobic (paclitaxel, PTX) drugs co-delivery with bovine serum albumin nanoparticles (BSA NPs) incorporation. The results showed the average survival of gliosarcoma-bearing (MBR 614 or U87) mice receiving BSA/PTX NPs incorporated hydrogelGd/EPI increased to 63 days or 69 days with no tumor recurrence observed. Our synergistic strategy presents a new approach to the development of a local drug delivery system for the prevention of brain tumor recurrence.

Keywords: Thermosensitivity hydrogels, MRI traceability, sustained drug release, tumor recurrence, brain tumor.


Citation styles

APA
Lin, F.W., Chen, P.Y., Wei, K.C., Huang, C.Y., Wang, C.K., Yang, H.W. (2017). Rapid In Situ MRI Traceable Gel-forming Dual-drug Delivery for Synergistic Therapy of Brain Tumor. Theranostics, 7(9), 2524-2536. https://doi.org/10.7150/thno.19856.

ACS
Lin, F.W.; Chen, P.Y.; Wei, K.C.; Huang, C.Y.; Wang, C.K.; Yang, H.W. Rapid In Situ MRI Traceable Gel-forming Dual-drug Delivery for Synergistic Therapy of Brain Tumor. Theranostics 2017, 7 (9), 2524-2536. DOI: 10.7150/thno.19856.

NLM
Lin FW, Chen PY, Wei KC, Huang CY, Wang CK, Yang HW. Rapid In Situ MRI Traceable Gel-forming Dual-drug Delivery for Synergistic Therapy of Brain Tumor. Theranostics 2017; 7(9):2524-2536. doi:10.7150/thno.19856. https://www.thno.org/v07p2524.htm

CSE
Lin FW, Chen PY, Wei KC, Huang CY, Wang CK, Yang HW. 2017. Rapid In Situ MRI Traceable Gel-forming Dual-drug Delivery for Synergistic Therapy of Brain Tumor. Theranostics. 7(9):2524-2536.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image